KKH Kaufm Nnische Krankenkasse Tender

Contract notice: Conclusion of non-exclusive discount agreements according to § 130a para. 8 sgb v to the in ii.2.4. mentioned active substances with the possibility of closing within the framework of the so-called open-house procedure. The commercial health insurance fund - kkh (hereinafter kkh) pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with § 130a paragraph 8 sgb v for the active ingredient(s) within the framework of a so-called "open-house procedure". With the specification of uniform contract conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or groups of pharmaceutical companies will be able to conclude or join a discount contract according to § 130a para. 8 sgb v for the above-mentioned active substance. interested pharmaceutical companies can apply to the under l.1. request the participation documents and the contract from the contact address provided.The commercial health insurance fund - kkh (hereinafter kkh) pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with section 130a paragraph 8 social code v for the following active ingredients (atc) and possibly restricting them to certain dosage forms as part of a so-called "open-house procedure " to conclude: nitisinone (atc: a16ax04) sapropterin (atc: a16ax07) carglumic acid (atc: a16aa05) under the specification of uniform contract conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or groups of pharmaceutical companies will be able to conclude or join a discount contract according to § 130a para. 8 sgb v for the above-mentioned active substance. interested pharmaceutical companies can apply to the under l.1. request the participation documents and the contract from the contact address provided. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, fully completed and signed. a contract will be concluded with each pharmaceutical company that meets the participation requirements. there is no exclusivity. joining or concluding a contract can take place at any time and under the same conditions. individual contract negotiations are not carried out. should the kkh conduct an open tender for exclusive contracts for the active ingredients during the contract period, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions.